Rigel Pharmaceuticals (RIGL) Reports 33% RBC-TI Rate for R289 in MDS, Receives FDA Designations
Rigel Pharmaceuticals (RIGL) disclosed Phase 1b data showing 33% of MDS patients achieved transfusion independence with R289, which received FDA Orphan Drug and Fast Track designations.